Dual Target Ligands with 4-tert-Butylphenoxy Scaffold as Histamine H3 Receptor Antagonists and Monoamine Oxidase B Inhibitors
Open Access
- 12 May 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (10), 3411
- https://doi.org/10.3390/ijms21103411
Abstract
Dual target ligands are a promising concept for the treatment of Parkinson’s disease (PD). A combination of monoamine oxidase B (MAO B) inhibition with histamine H3 receptor (H3R) antagonism could have positive effects on dopamine regulation. Thus, a series of twenty-seven 4-tert-butylphenoxyalkoxyamines were designed as potential dual-target ligands for PD based on the structure of 1-(3-(4-tert-butylphenoxy)propyl)piperidine (DL76). Probed modifications included the introduction of different cyclic amines and elongation of the alkyl chain. Synthesized compounds were investigated for human H3R (hH3R) affinity and human MAO B (hMAO B) inhibitory activity. Most compounds showed good hH3R affinities with Ki values below 400 nM, and some of them showed potent inhibitory activity for hMAO B with IC50 values below 50 nM. However, the most balanced activity against both biological targets showed DL76 (hH3R: Ki = 38 nM and hMAO B: IC50 = 48 nM). Thus, DL76 was chosen for further studies, revealing the nontoxic nature of DL76 in HEK293 and neuroblastoma SH-SY5Ycells. However, no neuroprotective effect was observed for DL76 in hydrogen peroxide-treated neuroblastoma SH-SY5Y cells. Furthermore, in vivo studies showed antiparkinsonian activity of DL76 in haloperidol-induced catalepsy (Cross Leg Position Test) at a dose of 50 mg/kg body weight.Funding Information
- National Science Centre, Poland (UMO-2016/23/B/NZ7/02327, 2019/03/X/NZ7/00180)
- German Research Foundation (DFG INST 208/664-1 FUGG)
This publication has 27 references indexed in Scilit:
- Chlorophenoxy aminoalkyl derivatives as histamine H3R ligands and antiseizure agentsBioorganic & Medicinal Chemistry, 2016
- International Union of Basic and Clinical Pharmacology. XCVIII. Histamine ReceptorsPharmacological Reviews, 2015
- Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyondFuture Medicinal Chemistry, 2015
- Indazole- and Indole-5-carboxamides: Selective and Reversible Monoamine Oxidase B Inhibitors with Subnanomolar PotencyJournal of Medicinal Chemistry, 2014
- Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the diseaseBritish Journal of Pharmacology, 2011
- Receptor-specific functional efficacies of alkyl imidazoles as dual histamine H3/H4 receptor ligandsEuropean Journal of Pharmacology, 2011
- Ether derivatives of 3-piperidinopropan-1-ol as non-imidazole histamine H3 receptor antagonistsBioorganic & Medicinal Chemistry, 2006
- Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A2A receptors in the caudate‐putamen of ratsEuropean Journal of Neuroscience, 2001
- A One-Step Fluorometric Method for the Continuous Measurement of Monoamine Oxidase ActivityAnalytical Biochemistry, 1997
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973